Harvard Apparatus Regenerative Technology (Harvard Apparatus Regenerative Technology) COGS-to-Revenue : 0.21 (As of Mar. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Harvard Apparatus Regenerative Technology COGS-to-Revenue?

Harvard Apparatus Regenerative Technology's Cost of Goods Sold for the three months ended in Mar. 2024 was $0.01 Mil. Its Revenue for the three months ended in Mar. 2024 was $0.06 Mil.

Harvard Apparatus Regenerative Technology's COGS to Revenue for the three months ended in Mar. 2024 was 0.21.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Harvard Apparatus Regenerative Technology's Gross Margin % for the three months ended in Mar. 2024 was 78.95%.

Harvard Apparatus Regenerative Technology COGS-to-Revenue Historical Data

The historical data trend for Harvard Apparatus Regenerative Technology's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harvard Apparatus Regenerative Technology COGS-to-Revenue Chart

Harvard Apparatus Regenerative Technology Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.23

Harvard Apparatus Regenerative Technology Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
COGS-to-Revenue	Get a 7-Day Free Trial															-	-	0.33	0.17	0.21

Harvard Apparatus Regenerative Technology COGS-to-Revenue Calculation

Harvard Apparatus Regenerative Technology's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0.024	/	0.103
	=	0.23

Harvard Apparatus Regenerative Technology's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0.012	/	0.057
	=	0.21

Harvard Apparatus Regenerative Technology (OTCPK:HRGN) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Harvard Apparatus Regenerative Technology's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0.012 / 0.057
	=	78.95 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Harvard Apparatus Regenerative Technology COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Harvard Apparatus Regenerative Technology's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Harvard Apparatus Regenerative Technology (Harvard Apparatus Regenerative Technology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Harvard Apparatus Regenerative Technology Inc (OTCPK:HRGN) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

84 October Hill Road, Suite 11, Holliston, MA, USA, 01746

Website

https://www.biostage.com

Harvard Apparatus Regenerative Technology Inc is a clinical-stage biotechnology company developing regenerative-medicine treatments for disorders of the gastrointestinal system and the airway resulting from cancer, trauma, or birth defects. The company's technology is based on its proprietary cell-therapy platform that uses a patient's own stem cells to regenerate and restore function to damaged organs.

Executives

Junli He	director	C/O NO.1, COUNTRY GARDEN ROAD, BEIJIAO TOWN, SHUNDE DISTRICT, FOSHAN F4 528300
James E. Shmerling	director	975 JOHNSON FERRY ROAD, SUITE 450, ATLANTA GA 30342
Dst Capital Llc	10 percent owner	C/O BIOSTAGE, INC., 84 OCTOBER HILL ROAD, HOLLISTON MA 01746
Ronald J Packard	director	2300 CORPORATE PARK DRIVE, HERNDON VA 20171
Jing Chen	director	C/O BIOSTAGE,INC., 84 OCTOBER HILL ROAD, HOLLISTON MA 02110
Hong Yu	officer: President	C/O BIOSTAGE, INC. 84 OCTOBER HILL ROAD, HOLLISTON MA 01746
Damasio Joseph Luis Jr	officer: Chief Financial Officer	14 NORFOLK AVENUE, SOUTH EASTON MA 02375
David Green	director, officer: See Remarks	C/O HARVARD BIOSCIENCE INC, 84 OCTOBER HILL ROAD, HOLLISTON MA 01746-1371
William Fodor	officer: Chief Scientific Officer	C/O BIOSTAGE, INC., 84 OCTOBER HILL ROAD, HOLLISTON MA 01746
Peter A. Pellegrino	officer: Interim VP of Finance	C/O BIOSTAGE, INC., 84 OCTOBER HILL ROAD, HOLLISTON MA 01746
Herman Sanchez	director	84 OCTOBER HILL ROAD, SUITE 11, HOLLISTON MA 01746
James Mastridge	officer: See Remarks	C/O BIOSTAGE, INC., 84 OCTOBER HILL RD., HOLLISTON MA 01746
Jeffrey E Young	director	60 WESTVIEW STREET, LEXINGTON MA 02421
Wei Zhang	director	C/O BIOSTAGE, INC., 84 OCTOBER HILL ROAD, HOLLISTON MA 01746
Ting Li	director	C/O BIOSTAGE, INC., 84 OCTOBER HILL RD., HOLLISTON MA 01746